Rituximab: In rheumatoid arthritis

BioDrugs

Volumn 21, Issue 5, 2007, Pages 333-341

  Frampton, James E ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Rheumatoid arthritis; Rituximab, therapeutic use

Indexed keywords

ADALIMUMAB; CD20 ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RITUXIMAB; TUMOR NECROSIS FACTOR ANTIBODY;

ANGIONEUROTIC EDEMA; ANXIETY; ARTHRALGIA; ASTHENIA; B LYMPHOCYTE; BRONCHITIS; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; COUGHING; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; DYSPEPSIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOTENSION; IMMUNOPATHOGENESIS; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; MONOTHERAPY; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; REVIEW; RHEUMATOID ARTHRITIS; RHINITIS; RHINOPHARYNGITIS; RIGOR; SIDE EFFECT; SINUSITIS; SNEEZING; STEADY STATE; THROAT IRRITATION; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; INFUSIONS, INTRAVENOUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 34948850964     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200721050-00005     Document Type: Review

References (55)

1. Doan T, Massarotti E. Rheumatoid arthritis: an overview of new and emerging therapies. J Clin Pharmacol 2005 Jul; 45 (7): 751-62
2. Smolen JS, Redlich K, Zwerina J, et al. Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects. Clin Rev Allergy Immunol 2005 Jun; 28 (3): 239-48
3. Voll RE, Kalden JR. Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis? Ann N Y Acad Sci 2005 Jun; 1051: 799-810
4. Blumberg SN, Fox DA. Rheumatoid arthritis: guidelines for emerging therapies. Am J Manag Care 2001 Jun; 7 (6): 617-26
5. Goldblatt F, Isenberg DA. New therapies for rheumatoid arthritis. Clin Exp Immunol 2005 May; 140 (2): 195-204
6. Keystone E. B cell targeted therapies. Arthritis Res Ther 2005; 7 Suppl. 3: S13-8
7. Shaw T, Quan J, Totoritis MC. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum Dis 2003 Nov; 62 Suppl. 2: ii55-9
8. Kotzin BL. The role of B cells in the pathogenesis of rheumatoid arthritis. J Rheumatol Suppl 2005 Feb; 73: 14-8
9. Looney RJ. B cell-targeted therapy for rheumatoid arthritis: an update on the evidence. Drugs 2006; 66 (5): 625-39
10. Lee SJ, Yedla P, Kavanaugh A. Secondary immune deficiencies associated with biological therapeutics. Curr Allergy Asthma Rep 2003 Sep; 3 (5): 389-95
11. American College of Rheumatology Subcommittee on Rheumatoid Arthritis guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002 Feb; 46 (2): 328-46
12. Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet Epub 2007 Jun 12
13. Fan PT, Leong KH. The use of biological agents in the treatment of rheumatoid arthritis. Ann Acad Med Singapore 2007 Feb; 36 (2): 128-7
14. Siddiqui MA. The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence. Curr Opin Rheumatol 2007 May; 19 (3): 308-13
15. Koller MD. Targeted therapy in rheumatoid arthritis. Wien Med Wochenschr 2006 Jan; 156 (1-2): 53-60
16. Biogen Idec Inc. and Genentech Inc. Rituxan® rituximab [prescribing information]. San Francisco (CA): Biogen Idec Inc., 2006
17. Roche Products Ltd. Mabthera 100mg and 500mg concentrate for solution for infusion: summary of product characteristics. Welwyn Garden City: Roche Products Ltd, 2007 [Data on file]
18. Summers KM, Kockler DR. Rituximab treatment of refractory rheumatoid arthritis. Ann Pharmacother 2005 Dec; 39 (12): 2091-5
19. De Vita S, Quartuccio L. Treatment of rheumatoid arthritis with rituximab: an update and possible indications. Autoimmun Rev 2006 Aug; 5 (7): 443-8
20. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Arthritis Rheum 2006 May; 54 (5): 1390-400
21. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004 Jun 17; 350 (25): 2572-81
22. Higashida J, Wun T, Schmidt S, et al. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment. J Rheumatol 2005 Nov; 32 (11): 2109-15
23. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006 Sep; 54 (9): 2793-806
24. Hoffmann-La Roche Ltd. Rituxan® (rituximab). Product monograph [online]. Available from URL: http://www.rochecanada.com [Accessed 2006 Aug 9]
25. Smolen JS, Betteridge N, Breedveld FC, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66 (2): 143-50
26. National Institute for Health and Clinical Excellence. TA 126 rheumatoid arthritis (refractory) - rituximab: guidance [online]. Available from URL: http://guidance.nice.org.uk [Accessed 2007 Sep 18]
27. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001; 40: 205-11
28. Edwards JC, Leandro MJ, Cambridge G. B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders. Biochem Soc Trans 2002; 30: 824-8
29. Szodoray P, Alex P, Dandapani V, et al. Apoptotic effect of rituximab on peripheral blood B cells in rheumatoid arthritis. Scand J Immunol 2004 Jul-Aug; 60 (1-2): 209-18
30. Pavelka K, Emery P, Filipowicz-Sosnowksa A, et al. Efficacy and safety following repeated courses of rituximab in patients with active rheumatoid arthritis [abstract no. SAT0080]. Ann Rheum Dis 2005; 64 (Suppl. III): 435. Plus poster presented at the Annual European Congress of Rheumatology; 2005 Jun 8-435. Plus poster presented at the Annual European Congress of Rheumatology; 211; Vienna
31. Leandro MJ, Cambridge G, Ehrenstein MR, et al. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006 Feb; 54 (2): 613-20
32. Ng CM, Bruno R, Combs D, et al. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 2005 Jul; 45 (7): 792-801
33. Breedveld FC, Agarwal S, Yin M, et al. Relationship between clinical response, rituximab pharmacokinetics, and peripheral B cell levels in rheumatoid arthritis [abstract no. 279]. Arthritis Rheum 2005; 52 (9 Suppl.): S138. Plus poster presented at the 69th Annual Scientific Meeting of the American College of Rheumatology and the 40th Annual Meeting of the Association of Rheumatology Health Professionals; 2005 Nov 12-17; San Diego (CA).
34. Keystone EC, Burmester GR, Furie R, et al. Improved quality of life with rituximab plus methotrexate in patients with active rheumatoid arthritis who experienced inadequate response to one or more anti-TNF-alpha therapies [abstract no. 287]. Arthritis Rheum 2005; 52 (Suppl. 9): S141-2. Plus poster presented at the 69th Annual Scientific Meeting of American College of Rheumatology and the 40th Annual Meeting of the Association of Rheumatology Health Professionals; 2005 Nov 12-17; San Diego (CA)
35. Cohen S, Emery P, Greenwald M, et al. Prolonged efficacy of rituximab in rheumatoid arthritis patients with inadequate response to one or more TNF inhibitors: 1-year follow-up of a subset of patients receiving a single course in a controlled trial (REFLEX study) [abstract no. THU0220]. Ann Rheum Dis 2006 Jul; 65 (Suppl. II): 183
36. Keystone E, Emery P, Peterfy CD, et al. Prevention of joint structural damage at 1 year with rituximab in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (REFLEX study) [abstract no. OP0016]. Ann Rheum Dis 2006; 65 Suppl. 11: 58
37. Kielhorn A, Bombardieri S, Aultman R, et al. Rituximab improves health-related quality of life as measured by the SF-36: domain score results from the REFLEX study [abstract no. FRI0126]. Ann Rheum Dis 2006 Jul; 65 (Suppl. II): 324. Plus poster presented at the Annual European Congress of Rheumatology; 2006 Jun 21-324. Plus poster presented at the Annual European Congress of Rheumatology;24; Amsterdam
38. Tak PP, Cohen S, Emery P, et al. Clinical response following the first treatment course with rituximab: effect of baseline autoantibody status (RF, anti-CCP) [abstract no. FRI0192]. Ann Rheum Dis 2007; 66 (Suppl. II): 338
39. Smolen J, Kavanaugh A, Tony HP, et al. Rituximab significantly improves the clinical and simplified disease activity index (CDAI, SDAI) scores in patients with rheumatoid arthritis and an inadequate response to TNF inhibitors (REFLEX) [abstract no. SAT0033]. Ann Rheum Dis 2007; 66 (Suppl. II): 439
40. Keystone E, Emery P, Peterfy CG, et al. Inhibition of radiographic progression with rituximab is not dependent on clinical efficacy; results from a study in rheumatoid arthritis patients with inadequate response to one or more TNF inhibitors (REFLEX) [abstract no. SAT0011]. Ann Rheum Dis 2007; 66 (Suppl. II): 431
41. Cohen S, Dougados M, Genovese M, et al. Consistent inhibition of structural damage progression by rituximab in medically important subgroups of patients with an inadequate response to TNF inhibitors: week 56 REFLEX results [abstract no. SAT0002]. Ann Rheum Dis 2007; 66 (Suppl. II): 428
42. Mease PJ, Keystone E, Kaell A, et al. Predicting outcome of a second course of rituximab for rheumatoid arthritis [abstract no. SAT0019]. Ann Rheum Dis 2007; 66 (Suppl. II): 434
43. Kremer JM, Tony H, Tak PP, et al. Efficacy of rituximab in active RA patients with an inadequate response to one or more TNF inhibitors [abstract no. FRI0133]. Ann Rheum Dis 2006 Jul; 65 (Suppl. II): 326. Plus poster presented at the Annual European Congress of Rheumatology; 2006 Jun 21-326. Plus poster presented at the Annual European Congress of Rheumatology;24; Amsterdam
44. Tak PP, Mease P, Bombardieri S, et al. Repeat treatment with rituximab improves physical function and quality of life in patients with rheumatoid arthritis and an inadequate response to TNF inhibitors [abstract no. SAT0175]. Ann Rheum Dis 2006 Jul; 65 (Suppl. 11): 503
45. Kremer JM, Tony HP, Genovese MC, et al. Repeat treatment with rituximab in active RA patients: long-term efficacy in patients with one versus two or more prior TNF inhibitors [abstract no. SAT0014]. Ann Rheum Dis 2007; 66 (Suppl. II): 432
46. Keystone E, Fleischmann RM, Emery P, et al. Repeated treatment courses of rituximab in rheumatoid arthritis: sustained efficacy in patients with an inadequate response to one or more TNF inhibitors [abstract no. SAT0012]. Ann Rheum Dis 2007; 66 (Suppl. II): 432
47. Finckh A, Ciurea A, Brulhart L, et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007 Apr 27; 56 (5): 1417-23
48. Data on file. F. Hoffman-La Roche Ltd, 2007
49. Mistry B, McCormick J, Diamantopoulos A, et al. Cost-utility analysis of ritux-imab as a new therapeutic option for rheumatoid arthritis patients in Canada [abstract no. PAR 6 plus poster]. Value Health 2006 Nov; 9 (6): A222
50. Kielhorn A, Rubbert A, Porter D, et al. Cost-effectiveness of rituximab therapy for rheumatoid arthritis: a pan-European analysis [abstract no. PAR10]. Value Health 2006; 9 (3): 27. Plus poster presented at the 11th International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2006 May 20-24; Philadelphia (PA).
51. Pompen M, Diamantopoulos A, Kievit W, et al. Economic consequences of providing rituximab as a treatment alternative for rheumatoid arthritis in the Netherlands [abstract no. THU0471]. Ann Rheum Dis 2007; 66 (Suppl. II): 272
52. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005 Oct; 31 (6): 456-73
53. van Vollenhoven RF, Emery P, Bingham C, et al. Long-term safety data from extended follow-up and repeat use of rituximab in rheumatoid arthritis [abstract no. OP0119]. Ann Rheum Dis 2007; 66 (Suppl. II): 88
54. van Vollenhoven RF, Emery Pl, Bingham C, et al. Safety of rituximab in rheumatoid arthritis: results of a pooled analysis [abstract no. FRI0151]. Ann Rheum Dis 2006 Jul; 65 Suppl. 11: 332
55. Emery P, Fleischmann RM, Pavelka K, et al. Safety and tolerability of rituximab retreatment in patients with active rheumatoid arthritis [abstract no. 860]. Arthritis Rheum 2005; 52 (9 Suppl.): 341. Plus poster presented at the 69th Annual Scientific Meeting of the American College of Rheumatology and the 40th Annual Meeting of the Association of Rheumatology Health Professionals; 2005 Nov 12-17; San Diego (CA).